Pronounced formation of 5-OH-dopa at enzymatic oxidation of DOPA in the presence of ascorbic acid
Hansson, C.; Rorsman, H.; Rosengren, E.
Acta Dermato-Venereologica 61(2): 147-148
1981
ISSN/ISBN: 0001-5555 PMID: 6165191 Document Number: 173289
The recently discovered intermediate product in melanin formation, 5-OH-dopa, is formed in large amounts when dopa is oxidized by tyrosinase in the presence of ascorbic acid.
Document emailed within 1 workday
Related Documents
Tran, N. 1974: Automated radiometric assays of enzymatic and nonenzymatic oxidation of DOPA in vitro Journal of Laboratory and Clinical Medicine 84(2): 287-291Bergonzi, P.; Chiurulla, C.; Gambi, D.; Mennuni, G.; Pinto, F. 1975: L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment Acta Neurologica Belgica 75(1): 5-10
Bizzarri, B.Mattia.; Tortolini, S.; Rotelli, L.; Botta, G.; Saladino, R. 2015: Current Advances in L-DOPA and DOPA-Peptidomimetics: Chemistry, Applications and Biological Activity Current Medicinal Chemistry 22(36): 4138-4165
Riley, P.A. 1999: The great DOPA mystery: the source and significance of DOPA in phase i melanogenesis Cellular and Molecular Biology 45(7): 951-960
Guillard, A. 1972: Treatment of Parkinson syndromes with L-Dopa and the association of L-Dopa and a decarboxylase inhibitor Bruxelles Medical 52(10): 673-680
Vasil'ev, V.N. 1980: Effect of a test with 0.1 g of L-DOPA on the dynamics of urinary excretion of catecholamines and DOPA in schizophrenic patients Voprosy Meditsinskoi Khimii 26(6): 782-786
Blair, M.L.; Reid, I.A.; Ganong, W.F. 1977: Effect of L-dopa on plasma renin activity with and without inhibition of extracerebral dopa decarboxylase in dogs Journal of Pharmacology and Experimental Therapeutics 202(1): 209-215
Gauthier, G.; de Ajuriaguerra, J.; Geissbuhler, F.; Simona, B.; Constantinidis, J.; Yanniotis, G.; Krassoievitch, M.; Eisenring, J.J.; Tissot, R. 1971: Substitutive therapy in Parkinson's syndromes. L-dopa plus peripheral decarboxylase inhibitor or 3-0-methyl dopa? La Presse Medicale 79(3): 91-92
Routh, J.I.; Bannow, R.E.; Fincham, R.W.; Stoll, J.L. 1971: Excretion of L-dopa and its metabolites in urine of Parkinson's disease patients receiving L-dopa therapy Clinical Chemistry 17(9): 867-871
Zabel, M. 1979: Ultrastructure of thyroid C cells following long-term administration of 1-DOPA or alpha-methyl-DOPA Acta Medica Polona 20(1): 53-54
Muenter, M.D.; Tyce, G.M. 1971: L-dopa therapy of Parkinson's disease: plasma L-dopa concentration, therapeutic response, and side effects Mayo Clinic Proceedings 46(4): 231-239
Robak, J.; Kopacz, M. 1989: The influence of sulfonated bioflavonoids on enzymatic oxidation of arachidonic acid and on non-enzymatic lipid oxidation Polish Journal of Pharmacology and Pharmacy 41(5): 469-473
Pontiroli, A.E.; Castegnaro, E.; Vettaro, M.P.; Viberti, G.C.; Pozza, G. 1977: Stimulatory effect of the dopa-decarboxylase inhibitor Ro 4-4602 on prolactin release; inhibition by l-dopa, metergoline, methysergide and 2-Br-alpha-ergocryptine Acta Endocrinologica 84(1): 36-44
Indo, T.; Takahashi, A. 1987: Should L-dopa therapy for Parkinson's disease be started early or late? Clinical course of the major tetrad in 122 Parkinsonian patients treated with L-dopa over 14 years Rinsho Shinkeigaku 27(11): 1419-1422
Geissbuhler, F.; Eisenring, J.J.; Friedli, P.; Bartholini, G.; Tissot, R. 1972: Cerebral and peripheral L-dopa uptake in patients with parkinsonian, depressive or manic syndromes administered L-dopa by perfusion combined or not with a decarboxylase inhibitor. Pharmacological effects L'Encephale 61(2): 127-148
Christiani, K.; Möller, W.D. 1973: Drug therapy of Parkinson's syndrome. Clinical long-term study using L-dopa and the drug conbination L-dopa-decarboxylase inhibitor Münchener Medizinische Wochenschrift 115(16): 711-713
Hefti, F.; Melamed, E.; Wurtman, R.J. 1981: The site of dopamine formation in rat striatum after L-dopa administration Journal of Pharmacology and Experimental Therapeutics 217(1): 189-197
Schachtschabel, D.O.; Pfab, R.; Paul, N.; Hess, F. 1988: Augmentation by L-dopa of growth inhibition and melanin formation of X-irradiated Harding-Passey melanoma cells in culture Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft . 164(7): 419-424
Nikiragina, G.P.; Khoreva, S.A. 1988: A comprehensive method of determining catecholamines, DOPA and 5-hydroxyindoleacetic acid in urine Laboratornoe Delo 9: 8-11
Extein, I.; Roth, R.H.; Bowers, M.B. 1974: Accumulation of 3H-homovanillic acid in rabbit brain and cerebrospinal fluid following intravenous 3H-L-dopa Biological Psychiatry 9(2): 161-170